

37 C.F.R. § 1.8

I hereby certify that this correspondence is being electronically filed with the United States Patent and Trademark Office via EFS-Web on the date below:

October 31, 2007 Electronic signature: / Svitlana Anderson /
Date Svitlana Anderson

PTO/SB/44 (09-07)

Approved for use through 08/31/2010. OMB 0651-0033

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

Page 2 of 2

PATENT NO.	:	7,008,633
APPLICATION NO.	:	10/024,678
ISSUE DATE	:	March 7, 2006
INVENTOR(S)	:	David J. Yang et al.

In Col. 70, line 67, "chiorella" should read -- chlorella --.

In Col. 71, line 2, "QIO" should read -- Q10--.

In Col. 71, line 13, "ocinium" should read -- ocimum --.

In Col. 71, line 14, "pay" should read -- pau ---.

In Col. 71, line 21, “vohimbe” should read -- yohimbe --.

In Col. 71, line 41, "svrinaes" should read -- syringes --.

In Col. 71, line 58, “polyglutaxnate” should read -- polyglutamate --.

In Col. 71, line 63, "Ra.²⁺, or Be²⁺." should read -- Ra²⁺, Sn²⁺, or Be²⁺. --.

In Col. 72, line 27, "meiphalan" should read -- melphalan --.

In Col. 72, line 31, after the occurrence of “trimethoprim,” insert --

metronidazole, clindamycin, mupirocin, amphotericin B, rifampin, fluconazole, or a combination thereof. --.

In Col. 72, line 41, “epmephrine” should read -- epinephrine --.

In Col. 72, line 42, “acetyicholine” should read -- acetylcholine --.

In Col. 72, line 43, “vasopressin.” should read -- vasopressin, --.

In Col. 72, line 43, "bradykinin." should read -- bradykinin, --.

In Col. 72, line 47, "amuiobutyric" should read -- aminobutyric --.

In Col. 72, line 59, "thymopoietin." should read -- thymopoietin, --.

In Col. 73, line 2-3, "*ras ; myc, raf, erb, src, fms, jun, trk, ret, gsp, hst, bcl abl,*" apply *Italic front*.

In Col. 74, line 22, “in situ” apply Italic font.

In Col. 74, line 29, “in situ” apply *Italic font*.

55100292.1

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Melissa L. Sistrunk, Ph. D. Reg. No. 45,579

FULBRIGHT & JAWORSKI L.L.P.

2

Fulbright Tower

1301 McKinney, Suite 5100

Houston, Texas 77010-3095